
    
      This study was divided into two phases conducted in sequence. Phase I was the
      Screening/Eligibility Phase, which included a Screening Visit, followed by two Eligibility
      Visits. Phase II was the randomized, double-masked, 6-week Treatment Phase which included
      on-therapy visits at Week 2 and Week 6. Travoprost was administered in 1 of 3 concentration
      levels (A-C), where A=lowest and C=highest.
    
  